67 results about "Trophoblast cell" patented technology

Provided is a mammalian-derived cell model that can be used in anti-aging drugs. The mammalian-derived extraembryonic trophoblast cell model is an early mammalian-derived extraembryonic stage. A change model and an aging evaluation index system for differentiating the cells into the extraembryonic trophoblast cells / organoids can be used for various anti-aging researches and target detection, anti-aging drug detection, screening and identification, research on innovative drugs / natural products, and development of chemicals and / or health foods and additives. Screening and identifying many resistances is helpful. Candidate targets of aging may be further mechanically and functionally validated for future therapeutic use. The screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of circ0005704 and related biological elements thereof in diagnosis and treatment of recurrent spontaneous abortion with unknown reasons. Researches find that differential expression and autophagy level of ULK1 in trophoblast cells of URSA patients are increased. High-throughput transcriptome sequencing is combined with bioinformatics analysis, and it is found that miR-26a-5p is down-regulated in URSA patients, is responsible for up-regulation of ULK1 and promotes autophagy of trophoblast cells, so that occurrence of URSA is increased. Through a high-throughput transcriptional set screening strategy and dual luciferase reporter gene analysis, it is found that circ0005704 enhances the expression of ULK1 through miR-26a-5p. In a word, the research of the invention shows that the circ0005704 / miR-26a-5p / ULK1 signal axis participates in the pathogenesis of URSA by adjusting the migration of the trophoblast cells, and a new target and scientific evidence are provided for the clinical treatment of URSA.

The invention discloses a trophoblast-free one-step culture method and application of tumor infiltrating lymphocytes, and particularly discloses a one-step amplification method of tumor infiltrating lymphocytes, which comprises the following steps: treating a tumor sample obtained from a subject into tumor segments; the tumor segments are cultured in a culture medium containing a CD3 agonist, a 4-1BB agonist and IL-2, so that an amplified tumor infiltration lymphocyte population is obtained, and the culture medium does not contain trophoblastic cells. Compared with the prior art, the method has the advantages that the required period for amplifying the tumor infiltrating lymphocytes is shorter, the cost is lower, the cell effect function is stronger, and the clinical application range of the tumor infiltrating lymphocyte therapy is widened.

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

An engineered trophoblast that expresses a cell surface molecule that specifically recognizes NKp46, the cell surface molecule comprising at least an antibody targeting NKp46 and a transmembrane domain. The invention discloses a cell culture medium and a method for amplifying NK cells. Compared with unengineered trophoblasts, the engineered trophoblasts are used for activating NK cells, and the amplification capacity of the NK cells and the killing activity of tumor cells can be enhanced.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention belongs to the technical field of bioengineering, and particularly relates to application of RPS26 recombinant protein in promoting early embryonic development of animals. Experiments show that after the RPS26 recombinant protein is added in the early-stage in-vitro embryo culture process of the lamb goats, the blastocyst rate of the lamb goats can be increased to 40.0%; meanwhile, the cell proportion of cell mass in the blastocyst can be remarkably increased, the cell proportion of trophoderm is reduced, and the total number of blastocyst cells is not influenced, so that the blastocyst development rate can be remarkably increased and the blastocyst quality can be improved by utilizing the RPS26 recombinant protein.

The present disclosure relates to antigen-binding molecules that bind to human and feline Human Trophoblast Cell Surface Antigen 2 (TROP2). The specific embodiments relate to antibody-drug conjugates (ADC) comprising saporin, mertansine and MMAE and chimeric antigen receptors (CAR) comprising said antigen-binding molecules for use in treatment of cancer.

The application relates to the field of biotechnology, in particular to application of CADM1 in preparation of a drug for gestational diabetes mellitus. The application comprises: using a detection reagent for detecting the expression level of CADM1 in preparation of a detection drug for gestational diabetes mellitus. The application is based on the previous research of the applicant that the expression level of CADM1 in the placental trophoblast of a gestational diabetes mellitus patient is reduced, and it is found in an in-vitro experiment that CADM1 can promote the proliferation, migration and invasion of the placental trophoblast cells, and by constructing an mRNA expression amount of CADM1 and a receiver operating characteristic curve of a subject of a GDM patient, it is indicated that the mRNA expression amount of CADM1 is related to the GDM patient, which indicates that CADM1 is related to the placental trophoblast of the gestational diabetes mellitus patient, and it is indicated that the detection of the gestational diabetes mellitus can be realized by detecting the detection reagent for detecting the expression level of CADM1.

Antibodies and antigen-binding fragments thereof specific to Trophoblast cell surface antigen 2 (Trop2). Also provided are anti-Trop2 antibody-drug conjugates (ADCs), Trop2-specific chimeric antigen receptor, and multispecific antigen binding proteins, such as bispecific T cell engagers (BiTEs), which bind to Trop2 and other targets. Further provided are compositions comprising the anti-Trop2 antibodies and antigen-binding fragments thereof, a method of diagnosis and cancer treatment employing the anti-Trop2 antibodies and antigen-binding fragments thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to application of beta cell protein in preparation of medicine for preventing and treating abortion. Research finds and verifies for the first time that application of beta cell protein (BTC) promotes invasion and tubulation processes of extravillus trophoblast cell line-HTR8 cells, BTC has an obvious rescue effect on embryo absorption in abortion model mice in early and middle stages of pregnancy, and BTC is injected into the abortion model mice in an intraperitoneal cavity in early and middle stages of pregnancy to increase placenta weight, so that the abortion model mice in early and middle stages of pregnancy have an obvious rescue effect on embryo absorption. Therefore, the BTC has a certain treatment effect on the abortion, so that the BTC has a good practical application value.

The application provides a blastocyst three-dimensional fitting reconstruction method and device, electronic equipment and storage medium. The method comprises the following steps: acquiring a plurality of focal plane images of a blastocyst; identifying a trophoblast cell mask and an inner cell mass mask in the blastocyst based on the plurality of focal plane images; constructing a trophoblast cell grid model and an inner cell mass grid model according to the trophoblast cell mask and the inner cell mass mask; constructing a depth map of the blastocyst according to the plurality of focal plane images; performing image fusion on the plurality of focal plane images to obtain a texture image; performing plane mapping according to the texture image and the depth map to generate an internal three-dimensional point cloud model of the blastocyst; constructing a three-dimensional geometric model of the blastocyst according to the trophoblast cell grid model, the inner cell mass grid model and the internal three-dimensional point cloud model; and mapping the texture image to the surface of the three-dimensional geometric model to generate a blastocyst three-dimensional model. The reconstruction based on the method does not affect the development of the embryo, and is low in cost and safe and reliable.

The separation and detection method comprises the following steps: rinsing placenta or villus tissues in a PBS (Phosphate Buffer Solution) added with a 1% penicillin-streptomycin double antibody solution, digesting the placenta or villus tissues into single cells by using a 1640 culture medium containing I-type and IV-type collagenase after the placenta or villus tissues are rinsed sufficiently to obtain a cell suspension, and culturing the cell suspension for later use; diluting and neutralizing collagenase digestive juice by using a 1640 culture medium containing high-temperature heat-inactivated fetal calf serum according to 5 times of volume; repeatedly discarding the precipitate, recovering the supernatant, and centrifuging to obtain a coarse migration body; and establishing a density gradient by using Optiprep as a density medium, washing the precipitate with PBS, and centrifuging to obtain the trophoblast cell-derived transporter. The invention provides a group of placenta villus trophoblast cell source migration body specific expression membrane proteins for the first time, and provides a method for specifically capturing the placenta trophoblast source migration body on the basis of the placenta villus trophoblast cell source migration body specific expression membrane proteins, so that a new direction for researching a trophoblast dysfunction related disease mechanism can be enriched.

The invention provides an NK cell in-vitro efficient culture system and application, the culture system comprises a K562 engineering cell, and six proteins of IL21, IL12, IL15, CD40L, CD155 and CD112 are expressed on a cell membrane of the K562 engineering cell in a transmembrane mode; the NK cell culture composition comprises the following components: a liquid serum-free cell culture medium, 1-5% (v / v) of autologous plasma, 100-250 [mu] g / ml of an astragalus extract and 200-500 [mu] g / ml of an angelica sinensis extract, and the dosage ratio of the astragalus extract to the angelica sinensis extract is 1: 2. The NK cell with high amplification multiple, high purity and high lethality can be obtained by a culture system established by taking the K562 engineering cell constructed by the invention as a trophoblast cell, taking an astragalus extract and an angelica sinensis extract as culture additives and taking PBMC as an original culture material, and the culture system has important significance for treating cancers by cell drugs.

The invention discloses a culture medium for goat trophoblast organoid, a culture method and application, and belongs to the field of goat trophoblast organoid culture. The method comprises the following steps: separating trophoblast tissues from a healthy goat placenta which is pregnant for 80-90 days, digesting the trophoblast tissues through type II collagenase to obtain primary cells, compounding the primary cells with matrigel, and performing three-dimensional culture in an improved trophoblast organ culture medium with specific components to form mature organs. The organ is of a typical three-dimensional structure, and KRT23 and SOX2 markers are stably expressed. The organoid culture system based on the goat primary trophoblast cells is established for the first time, gene modification is not needed, the in-vivo physiological status is highly simulated, and the culture system is standardized and good in repeatability. The constructed organoid can be used as an ideal in-vitro model for researching placenta development, evaluating drugs and toxins and modeling infectious diseases in the gestation period, and is of great significance in improving the reproductive research level of goats and the production benefits of animal husbandry.

The application discloses a simple and low-cost method for culturing canine NK cells in vitro and belongs to the technical field of cell culture. The method comprises the following steps: separating NK cells from peripheral blood of a dog, culturing the NK cells with a canine NK cell activation culture medium for 24-48 hours, then continuing to culture the NK cells with a canine NK cell expansion culture medium, adding the canine NK cell expansion culture medium after 48 hours, expanding the cells in a bottle when the cells are obviously expanded, otherwise maintaining the cells in the original bottle after centrifugation, adding liquid and expanding the cells in a bottle or culturing the cells in the original bottle every other day, and harvesting the canine NK cells after 12-18 days. The method provided by the application does not need to activate the canine NK cells by using engineered trophoblast cells and multiple cell factors, and does not need to activate the cells by using an antibody, so that the method is simple and low in cost, and the cultured canine NK cells normally express NKp46, do not express CD3 and CD5, and have normal inhibitory and killing tumor abilities.

The present invention belongs to the field of medical technology and specifically relates to the use of a mulberry leaf aqueous extract in improving adverse pregnancy outcomes caused by PM2.5. The mulberry leaf aqueous extract can effectively improve adverse pregnancy outcomes caused by PM2.5; the mulberry leaf aqueous extract prevents and treats adverse pregnancy outcomes caused by PM2.5 by reducing the biological damage to trophoblast cells caused by PM2.5.

The invention relates to the field of cell genetic engineering, and discloses a high-sensitivity embryo chromatin analysis method which comprises the following steps: S1, puncturing an embryo zona pellucida through a micromanipulation instrument, sucking 5-8 trophoblast cells, and immersing a sample into 4 DEG C chromatin stabilizing liquid containing 1mM of ethylenediamine tetraacetic acid and bovine serum albumin within 8 seconds after the sample is obtained; s2, processing the sample by adopting a gradient fixation method; s3, sequentially carrying out low-intensity ultrasonication and restriction enzyme combined treatment; s4, carrying out specific labeling by using a double-labeling probe system; s5, implementing two-stage signal amplification in the micro-fluidic chip; and S6, carrying out three-dimensional space conformation analysis by adopting a super-resolution microscope. A silicon nitride microscopic needle penetrates through the zona pellucida at a puncture angle of 75-85 degrees, and the suction speed is controlled to be 0.5 mu L / s in combination with a PID closed loop, so that the DNA fragmentation rate can be reduced to 2.1 + / -0.3% (the proportion of 5kb fragments is 98.5%), and the embryo survival rate is gt; the H3K9 acetylation modification level is improved by 5.3 times, and the chromatin accessibility is improved.

The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

The invention discloses a preparation method of feeder layer cells and application of the feeder layer cells in primary tumor cell culture, and belongs to the technical field of biology. The method comprises the following steps: digesting tumor tissues by using collagenase and hyaluronidase, resuspending cells by using a culture medium, passing through a cell sieve, inoculating into a culture vessel for culture, obtaining tumor-related fibroblasts through differential digestion, repeating the steps of culture and differential digestion, adding the obtained fibroblasts into a culture medium containing 25-35mu g / ml mitomycin C, and treating for 3-5 hours, thereby obtaining the tumor-related fibroblasts. And cleaning the cells with a fresh culture medium for 1-5 times to obtain the feeder layer cells. The operation process is simple, compared with general trophoblast cells 3T3-J2 (Kerafast company), the trophoblast cells 3T3-J2 are low in price and easy to obtain, the problem that the culture period is limited is solved, the prepared feeder layer cells can be directly applied to primary tumor cell culture, and the cost of primary tumor cell culture is further reduced.

Provided are anti-Trophoblast cell surface antigen 2 (TROP2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-TROP2 antibodies, vectors comprising such nucleic acids, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-TROP2 antibodies. Also provided are antibody drug conjugates (ADCs) comprising an anti-TROP2 antibody and an active moiety (e.g., a therapeutic moiety such as a toxin) and methods of making anti-TROP2 ADCs. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant TROP2 expression (e.g., cancer).

The present invention provides trophoblast cells, preparation methods, and uses thereof. Specifically, the present invention provides a fusion protein comprising the following elements fused together: (a) IL15; (b) TNFSF9 or an active fragment thereof; and (c) IL21. The present invention also provides trophoblast cells incorporating the fusion protein. The trophoblast cells of the present invention can significantly enhance the expansion multiple of natural killer cells and the expansion capacity of natural killer cells.

The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.

The invention provides application of hsacirc0069443 in preparation of a medicine for treating early pregnancy loss, and belongs to the technical field of molecular biology. The invention finds that the hsacirc0069443 is an important circRNA (Ribonucleic Acid) which causes the loss of early pregnancy. The hsacirc0069443 is down-regulated in a patient with early pregnancy loss, and the hsacirc0069443 is knocked down to inhibit proliferation, migration and invasion of trophoblast cells. The research finds that hsacirc0069443 can be secreted from trophoblast cells in an exosome form, migration and invasion of endometrial interstitial cells are promoted, and the endometrial gland epithelial cell EMT process is promoted by the exosome secreted by the trophoblast cells. The invention provides a new target for early pregnancy loss treatment.

The application aims to provide an application of a biological agent in treating placental dysfunction, and belongs to the technical field of medicine.The biological agent is composed of siRNA for inhibiting expression of a LOC101929800 gene, a transcript sequence of the LOC101929800 gene is SEQ ID NO.1 in the sequence listing, and a sequence of the siRNA is SEQ ID NO.10 and SEQ ID NO.11 in the sequence listing.The application finds that the siRNA can reverse the decrease of the invasion ability of the trophoblast cells caused by hypoxia-reoxygenation to a certain extent by transfecting the siRNA in the cells under hypoxia-reoxygenation, and therefore the siRNA can be used for preparing the biological agent for treating placental injury.

The invention provides a composition, a cell culture medium and application of the cell culture medium in establishment of trophoblast stem cells in bovine hatching blastocysts, and belongs to the technical field of cell engineering. The invention provides a composition. The composition comprises activin A, CHIR99021 and a recombinant human leukemia inhibition factor. After the composition is adopted to culture hatched blastocysts, bovine trophoblast stem cells are obtained in vitro, trophoblast cell specific markers are highly expressed in mRNA and protein levels, and the bovine trophoblast stem cells can be stably cultured in vitro for a long time. The composition not only can further enrich the culture system of the bovine trophoblast stem cells, but also can expand understanding of the difference of signal pathways causing the blastocysts in different stages of the cattle.

The invention provides a peripheral blood NK cell efficient amplification method which comprises the following steps: collecting peripheral blood and separating mononuclear cells, removing CD3 + lymphocytes by an immunomagnetic bead method to obtain initial NK cells, coating a culture plate with an anti-NKp46 antibody, performing first-stage activation under the combination of IL-2 and IL-12, and co-culturing with inactivated trophoblast cells to obtain the NK cells. Second-stage amplification is completed in a culture medium containing IL-15, IL-21, IL-33, NAC, melatonin and other additives, and finally, CD3-CD56 + cells are obtained through flow sorting; according to the method, the NK cell amplification multiple is larger than or equal to 1000 times, the purity is maintained to be 91% or above, the cell activity and killing activity are high, and an efficient and feasible scheme is provided for clinical cell therapy.

The present invention discloses an induced trophoblast stem cell, a preparation method and an application thereof, and relates to the field of biomedical technology. The preparation method comprises using human pluripotent stem cells as donor cells, and culturing them in an induction medium to derive induced trophoblast stem cells with the ability to proliferate indefinitely and differentiate into subtypes of trophoblast cells. The induction medium contains vitamin C, epidermal growth factor, a WNT pathway activator, a TGF-β pathway inhibitor, a ROCK pathway inhibitor and a histone deacetylase inhibitor. The present invention can expand the source of trophoblast stem cells and avoid ethical issues, and is helpful to study the mechanism of placental development and the occurrence and development of related diseases, and explore the process of in vitro embryo synthesis and embryo self-assembly.

The present disclosure relates generally to binding agents, such as antibodies and antigen binding fragments thereof, capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents capable of targeting tumor cells expressing TROP2 and their use for the treatment of cancer. A single domain antibody that specifically binds to an amino acid residue of the extracellular domain of TROP2 is provided.